Please assess the completion status of the following clinical trial:

Trial Title: First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic (stage IV) NSCLC~* Measurable disease according to RECIST v.1.0 2009~* KRAS, BRAF and PI3K wild type in primary tumor or metastatic tissue.~* Age ≥18~* PS \< 2~* Adequate organ function~Haematology:~* Neutrophil count ≥1.5x10\^9/L~* Platelet count ≥100x10\^9/L~* Leucocyte count \> 3,000/mm~Hepatic function:~* Total bilirubin ≤ 1.5 times the upper normal limit (UNL)~* Serum transaminases ≤ 2.5xUNL in absence of liver metastases, or ≤ 5xUNL in presence of liver metastases~Renal Function:~* Creatinine clearance ≥ 50 mL/min and serum creatinine ≤ 1.5xUNL~Metabolic function:~* Magnesium ≥ lower limit of normal.~* Calcium ≥ lower limit of normal.~Consent to translational research studies~Written informed consent~Exclusion Criteria:~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment/randomization, active severe infections or other concurrent disease.~* Known CNS metastasis (pretreatment routine assessment not required)~* Prior chemotherapy for metastatic disease~* Indication for radiation therapy or prior radiotherapy within 30 days before treatment start.~* Other malignant diseases within 5 years prior to inclusion in the study, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ.~* Other experimental therapy within 30 days prior to treatment initiation.~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.~* Patients pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.~* Patients (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).